Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellular Biomedicine has achieved 50% enrollment milestone in Phase I open label clinical research trial for knee osteoarthritis (KOA).
Subscribe to our email newsletter
The trial will test the safety and efficacy of intra-articular injections of autologous human adipose-derived mesenchymal progenitor cells (haMPC) to reduce inflammation and regenerate damaged joint tissues.
Cellular Biomedicine president Dr. William Cao said the patient enrollment achievement in the clinical trial is a milestone for CBMG.
"We anticipate that enrollment will continue to move quickly and the study is on schedule to complete its Phase I clinical trial," Cao added.
The trial, registered with the US National Institutes of Health (NIH), is conducted at Shanghai Renji Hospital in China.